Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPBWR1 | P48145 | 12/20 | 0.51 |
| ▸ | PDE1B | Q01064 | 4/20 | 0.49 |
| ▸ | PDE1A | P54750 | 2/20 | 0.49 |
| ▸ | PDE1C | Q14123 | 2/20 | 0.49 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | PKLR | P30613 | 1/20 | 0.45 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.42 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | DCTPP1 | Q9H773 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22912921 | 0.87 | PDE1B (0.49) | NPBWR1PDE1BPDE1APDE1CMCHR1 | |
| SCHEMBL31073966 | 0.81 | NPBWR1 (0.50) | NPBWR1PDE1BPDE1APDE1CMCHR1 | |
| SCHEMBL22912945 | 0.80 | PDE1A (0.50) | NPBWR1PDE1BPDE1APDE1CMCHR1 | |
| SCHEMBL20176607 | 0.80 | PDE1A (0.49) | NPBWR1PDE1BPDE1APDE1CMCHR1 | |
| SCHEMBL5091051 | 0.79 | BRD4 (0.53) | NPBWR1PDE1BPDE1APDE1CMCHR1 | |
| SCHEMBL29433484 | 0.79 | BRD4 (0.53) | NPBWR1PDE1BPDE1APDE1CMCHR1 | |
| SCHEMBL30959673 | 0.79 | NPBWR1 (0.49) | NPBWR1PDE1BPDE1APDE1CMCHR1 | |
| SCHEMBL23210996 | 0.78 | GRIN1 (0.58) | NPBWR1PDE1BGRIN1GRIN2B | |
| SCHEMBL16014472 | 0.78 | PDE1A (0.50) | NPBWR1PDE1BPDE1APDE1CMCHR1 | |
| SCHEMBL22139429 | 0.77 | NPBWR1 (0.48) | NPBWR1PDE1BPDE1APDE1CMCHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114929683-B | Pyridine derivatives as modulators of calcium activated chloride channels | 跨膜蛋白16A有限公司 | 2024-09-03 | — | — | CN | disclosed |
| EP-4003977-A1 | PYRIDINE DERIVATIVES AS CALCIUM-ACTIVATED CHLORIDE CHANNEL MODULATORS | TMEM16A LIMITED (GB) | 2022-06-01 | — | — | EP | disclosed |
| US-20220144803-A1 | PYRIDINE DERIVATIVES AS CALCIUM-ACTIVATED CHLORIDE CHANNEL MODULATORS | Enterprise Therapeutics Limited (GB) | 2022-05-12 | — | — | US | disclosed |
| WO-2021014172-A1 | PYRIDINE DERIVATIVES AS CALCIUM-ACTIVATED CHLORIDE CHANNEL MODULATORS | Enterprise Therapeutics Limited (GB) | 2021-01-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220144803-A1 | PYRIDINE DERIVATIVES AS CALCIUM-ACTIVATED CHLORIDE CHANNEL MODULATORS | TMEM109, CACNA1E, CACNA1A | NPBWR1 989/4885PDE1B 582/4885PDE1A 970/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.